Deposition of Aerosolized Lucinactant in Nonhuman Primates

J Aerosol Med Pulm Drug Deliv. 2020 Feb;33(1):21-33. doi: 10.1089/jamp.2018.1505. Epub 2019 Aug 22.

Abstract

Background: Lucinactant for inhalation is an investigational noninvasive, aerosolized surfactant replacement therapy for treatment of preterm neonates with respiratory distress syndrome. Lucinactant for inhalation consists of lyophilized lucinactant and the Aerosurf® Delivery System (ADS). The objective of this study was to characterize the total and regional pulmonary deposition of lucinactant delivered by the ADS in nonhuman primates (NHPs). Methods: Lucinactant was radiolabeled by the addition of technetium-99m (99mTc)-sulfur colloid. The radiolabeled aerosol was characterized and validated using a Mercer cascade impactor. An in vivo deposition study was performed in three cynomolgus macaques. Radiolabeled lucinactant was aerosolized using the ADS and delivered via nasal cannula under 5 cm H2O nasal continuous positive airway pressure (nCPAP) for 5-9 minutes. A two-dimensional planar image was acquired immediately after aerosol administration, followed by a three-dimensional single-photon emission computed tomography (SPECT) image and a second planar image. The images were analyzed to determine the pulmonary (lungs) and extrapulmonary (nose + mouth, trachea, stomach) distribution. The SPECT data were used to determine regional deposition. Results: The radiolabed lucinactant aerosol had a mass median aerodynamic diameter = 2.91 μm, geometric standard deviation (GSD) = 1.81, and an activity median aerodynamic diameter = 2.92 μm, GSD = 2.06. Aerosolized lucinactant was observed to deposit in the lungs (11.4%), nose + mouth (79.9%), trachea (7.3%), and stomach (1.4%). Analysis of the SPECT image demonstrated that the regional deposition within the lung was generally homogeneous. Aerosolized lucinactant was deposited in both the central (52.8% ± 1.2%) and peripheral (47.2% ± 1.2%) regions of the lungs. Conclusion: Aerosolized lucinactant, delivered using the ADS via constant flow nCPAP, is deposited in all regions of the lungs demonstrating that surfactant can be aerosolized and delivered noninvasively to NHPs.

Keywords: aerosol distribution; noninvasive delivery; regional lung aerosol deposition; surfactant aerosol.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Inhalation
  • Aerosols
  • Animals
  • Drug Combinations
  • Drug Delivery Systems*
  • Fatty Alcohols / administration & dosage*
  • Fatty Alcohols / pharmacokinetics
  • Humans
  • Lung / metabolism*
  • Macaca fascicularis
  • Phosphatidylglycerols / administration & dosage*
  • Phosphatidylglycerols / pharmacokinetics
  • Proteins / administration & dosage*
  • Proteins / pharmacokinetics
  • Pulmonary Surfactants / administration & dosage*
  • Pulmonary Surfactants / pharmacokinetics
  • Technetium
  • Tissue Distribution
  • Tomography, Emission-Computed, Single-Photon

Substances

  • Aerosols
  • Drug Combinations
  • Fatty Alcohols
  • Phosphatidylglycerols
  • Proteins
  • Pulmonary Surfactants
  • lucinactant
  • Technetium